# NCT05933577 (NCT05933577)

> A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05933577
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Melanoma
- Interventions: Intismeran autogene; Pembrolizumab; Placebo
- Enrollment: 1089
- Primary outcome: Recurrence-Free Survival (RFS)

## Commentary we found

- X threads: 25
- Podcasts: 6
- YouTube: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05933577

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05933577", "email": "<work email>"}; the inbox owner confirms by the emailed link.